Pediatric Oncology Fellowship
- Program Name: Pediatric Oncology Fellowship
- Program Description: The program curriculum use the American Academy of Pediatrics Oncology curriculum as a guide. Training is centered primarily on CCHE with formal collaboration with DF/BC.
- Track 1: is a 36-month fellowship in general pediatric oncology.
- Track 2: is a 12-month sub-specialty option for pediatric oncologists to develop expertise in a variety of pediatric oncology subspecialties.
- Track 3: is a 24-month subspecialty focus that would be available to other non-pediatric oncology specialists to develop expertise in a variety of pediatric oncology related subspecialties.
- Collaboration Dana-Farber Boston Children’s Cancer and Blood Disorders Center.
- Degree /Certificate: Training Certificate from the CCHF 57357 and DF/BC.
- Duration: Program duration is 36 months inclusive of vacation time (3 weeks per year in the first two years).
- Location: Based at CCHE Cairo, Egypt with a rotation to DFBC in Boston MA, USA. Other affiliated hospitals or institutions in the USA may also participate in the program.
- Mode of Delivery: On-Site live training.
- Program Content Model: Course content is set using the American Academy of Pediatric Oncology curriculum guidelines.
The program comprises a three-track option with the express purpose of increasing the number and skill level of pediatric oncologists as well as pediatric oncology sub-specialists in Egypt and the region.
The collaboration initiative is a joint effort between CCHF 57357 and DF/BC. The program is made up of three tracks:
- Number of Applicants: 12 Applicant.
- Short list: 9 Applicant.
- Selection Process Outcome “No. of participants”: 4 Fellows.
- No. of External Candidates: 0
- Participants Scientific Activities:
- Weekly Lectures.
- Study team meetings CCHE.
- Combined clinics CCHE (50%).
- Mortality and morbidity rounds CCHE.
- Visiting lecturers.
- Monthly video conferencing of difficult cases at both institutions.
- DFBC tumor board and other appropriate joint tutorial sessions.
- International Visits
- 1st Visit: April 2021 , “Dr. Leslie Liehman, Dr. Liliana Gomrinova & Dr. Mark Keirn”
- Visit Duration: 4 days (4th & 7th January 2020)
- Visit Goal:
- Clinical rounds.
- Research project follow-up.
- Committee meeting.
- PNOC Meeting.
- Case presentations.
- Visit Outcome: revising research projects, training the fellows how to make a clinical presentation on any case, the fellows presented cases and discuss with the committee about its treatment plan.
- 2nd Visit: July 2021 “Dr. Leslie Lehman, Dr. Liliana Gomrinova & Dr. Mark Keirn”
- Visit Duration: 4 days (4th to 7th July 2021)
- Visit Goals:
- Fellow’s assessment and evaluation.
- Written final exam for fellows 2018.
- OSCE exam for fellows 2018.
- Interviewing new applicants.
- Finalize selection process results and select the new patch 2021.
- Project discussions.
- Visit Outcome:
- Patch 2021 selection.
- Final exam for fellows 2018.
- Projects tracking.
- Followup fellows activities.
- Visit Duration: 4 days (31st of October, 2021 to 3rd of November, 2021)
- Visit Goals:
- Committee Meetings for revising all the fellows’ activities.
- Revising all the projects of the fellows from 2015 to 2020.
- Visit Outcome:
- Following the fellows’ activates.
- Revising all the projects' progress for 6 Patches.
- Participant Projects Sheet: *in appendix 1
- Publication Project: *in appendix 1
- Pass Rate (No. of successful candidates/Total no of candidates): 100%
Visitors: 2021 visits From Boston team. (3 visits)
3rd Visit: “Dr. Mark Kiern, DR Lei sly Lehman, and Dr. Liliana Joumnerova”
Pediatric Oncology Fellowship Research Projects
|Fellow Name||Class||Project title||Journal Name||Publication|
|Hisham Moneib||2014||Day +100 Platelet Count Predicts Survival After Allogeneic |
Stem-Cell Transplantation in
Children with Hematologic Malignancies.
|(Clinical Lymphoma, Myeloma and leukemia) 2019||https://www.clinical-lymphoma-myeloma-|
|Noura Mahmoud||2014||Outcome of Childhood Acute |
Children’s Cancer Hospital Egypt 57357 Experience.
|(Clinical Lymphoma, Myeloma and leukemia) 2018||https://www.clinical-lymphoma-myeloma-|
|Ahmed Emad||2015||Outcome of |
|(Pediatric Hematology Oncology. 2019)||https://journals.lww.com/jpho-online/|
|Ahmed Mahdy||2015||Incidence, risk factors, and outcome |
of blood stream infections
during the first 100 days post‐pediatric allogeneic
and autologous hematopoietic
stem cell transplantations
|(Pediatric transplantation, 2019)||https://onlinelibrary.wiley.com/|
|Mariam Elsherif||2015||MECOM gene overexpression in pediatric patients with acute myeloid leukemia||ACTA ONCOLOGICA||https://doi.org/10.1080/0284186X.2022.2025611||4.2|
|Programs||Start date||End date||No. of |
|Pediatric Oncology Fellowship cohort 1||1-Nov-14||Jul-17||4||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 2||1-Dec-15||Jul-18||6||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 3||1-Dec-16||Jul-19||6||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 4||1-Dec-17||Jul-20||6||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 5||1-Dec-18||Jul-21||6||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 6||1-Dec-19||Ongoing||4||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 7||1-Dec-20||Ongoing||4||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
|Pediatric Oncology Fellowship cohort 8||1-Dec-21||Ongoing||4||Dana Farber Boston Children's Cancer and Blood Disorders Center (DFBC)|
Pass Rate (No. of successful candidates / Total no of candidates): 100%